|Bid||155.61 x 800|
|Ask||156.04 x 800|
|Day's range||152.88 - 164.35|
|52-week range||90.29 - 464.00|
|Beta (5Y monthly)||-1.25|
|PE ratio (TTM)||4.93|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Pfizer (PFE) and BioNTech (BNTX) announce that the first participants in a clinical study on its Omicron-specific COVID-19 vaccine candidate have been dosed.
Moderna (MRNA) doses the first participant in a phase II study on its Omicron specific COVID-19 booster candidate in a mid-stage study.
Shares of coronavirus vaccine makers generally had a good Wednesday on the back of a coming push on additional jabs, plus a notable recommendation boost by a prominent investment bank. In contrast to the day's dip in the S&P 500 index, Moderna (NASDAQ: MRNA) stock enjoyed a 1.6% lift, Comirnaty vaccine co-developers Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) respectively rose by 0.9% and 2.7%, and perennial underdog Novavax (NASDAQ: NVAX) gained 2.6%.